nodes	percent_of_prediction	percent_of_DWPC	metapath
Avanafil—Angina unstable—Capecitabine—esophageal cancer	0.0398	0.0445	CcSEcCtD
Avanafil—Dyspnoea exertional—Capecitabine—esophageal cancer	0.0333	0.0372	CcSEcCtD
Avanafil—Abdominal pain lower—Capecitabine—esophageal cancer	0.0316	0.0353	CcSEcCtD
Avanafil—Pruritus genital—Capecitabine—esophageal cancer	0.0241	0.0269	CcSEcCtD
Avanafil—Rhinorrhoea—Cisplatin—esophageal cancer	0.0168	0.0188	CcSEcCtD
Avanafil—Deep vein thrombosis—Capecitabine—esophageal cancer	0.0165	0.0185	CcSEcCtD
Avanafil—Infection—Carboplatin—esophageal cancer	0.0165	0.0184	CcSEcCtD
Avanafil—Wheezing—Cisplatin—esophageal cancer	0.0132	0.0148	CcSEcCtD
Avanafil—Body temperature increased—Carboplatin—esophageal cancer	0.0131	0.0147	CcSEcCtD
Avanafil—Rhinorrhoea—Capecitabine—esophageal cancer	0.0124	0.0139	CcSEcCtD
Avanafil—Deep vein thrombosis—Methotrexate—esophageal cancer	0.0123	0.0138	CcSEcCtD
Avanafil—Gastrooesophageal reflux disease—Capecitabine—esophageal cancer	0.0111	0.0124	CcSEcCtD
Avanafil—Oropharyngeal pain—Capecitabine—esophageal cancer	0.0111	0.0124	CcSEcCtD
Avanafil—Nasal congestion—Cisplatin—esophageal cancer	0.0109	0.0121	CcSEcCtD
Avanafil—Blood bilirubin increased—Capecitabine—esophageal cancer	0.0106	0.0119	CcSEcCtD
Avanafil—Blood pressure increased—Capecitabine—esophageal cancer	0.0101	0.0112	CcSEcCtD
Avanafil—Influenza like illness—Capecitabine—esophageal cancer	0.00977	0.0109	CcSEcCtD
Avanafil—Blood creatinine increased—Cisplatin—esophageal cancer	0.00928	0.0104	CcSEcCtD
Avanafil—Breast disorder—Cisplatin—esophageal cancer	0.00895	0.01	CcSEcCtD
Avanafil—Nasopharyngitis—Cisplatin—esophageal cancer	0.00886	0.0099	CcSEcCtD
Avanafil—Diabetes mellitus—Capecitabine—esophageal cancer	0.00839	0.00938	CcSEcCtD
Avanafil—Abdominal discomfort—Cisplatin—esophageal cancer	0.00821	0.00917	CcSEcCtD
Avanafil—Hepatic enzyme increased—Methotrexate—esophageal cancer	0.00792	0.00884	CcSEcCtD
Avanafil—Hot flush—Capecitabine—esophageal cancer	0.0078	0.00872	CcSEcCtD
Avanafil—Menopausal symptoms—Capecitabine—esophageal cancer	0.00774	0.00865	CcSEcCtD
Avanafil—Pain in extremity—Capecitabine—esophageal cancer	0.0073	0.00816	CcSEcCtD
Avanafil—PDE5A—Nitric oxide stimulates guanylate cyclase—NOS2—esophageal cancer	0.00722	0.0687	CbGpPWpGaD
Avanafil—Blood creatinine increased—Capecitabine—esophageal cancer	0.00684	0.00764	CcSEcCtD
Avanafil—Urinary tract disorder—Cisplatin—esophageal cancer	0.00677	0.00756	CcSEcCtD
Avanafil—Connective tissue disorder—Cisplatin—esophageal cancer	0.00673	0.00752	CcSEcCtD
Avanafil—Urethral disorder—Cisplatin—esophageal cancer	0.00672	0.0075	CcSEcCtD
Avanafil—Breast disorder—Capecitabine—esophageal cancer	0.0066	0.00737	CcSEcCtD
Avanafil—Nasopharyngitis—Capecitabine—esophageal cancer	0.00653	0.00729	CcSEcCtD
Avanafil—Gastritis—Capecitabine—esophageal cancer	0.00646	0.00722	CcSEcCtD
Avanafil—PDE5A—Platelet homeostasis—GNG7—esophageal cancer	0.00646	0.0615	CbGpPWpGaD
Avanafil—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00644	0.00719	CcSEcCtD
Avanafil—Eye disorder—Cisplatin—esophageal cancer	0.0064	0.00715	CcSEcCtD
Avanafil—Flushing—Cisplatin—esophageal cancer	0.00636	0.00711	CcSEcCtD
Avanafil—Cardiac disorder—Cisplatin—esophageal cancer	0.00636	0.00711	CcSEcCtD
Avanafil—Influenza—Capecitabine—esophageal cancer	0.00631	0.00705	CcSEcCtD
Avanafil—Diabetes mellitus—Methotrexate—esophageal cancer	0.00625	0.00698	CcSEcCtD
Avanafil—Immune system disorder—Cisplatin—esophageal cancer	0.00619	0.00692	CcSEcCtD
Avanafil—Mediastinal disorder—Cisplatin—esophageal cancer	0.00617	0.0069	CcSEcCtD
Avanafil—Angina pectoris—Capecitabine—esophageal cancer	0.00615	0.00687	CcSEcCtD
Avanafil—Bronchitis—Capecitabine—esophageal cancer	0.00607	0.00678	CcSEcCtD
Avanafil—Abdominal discomfort—Capecitabine—esophageal cancer	0.00605	0.00676	CcSEcCtD
Avanafil—Malnutrition—Cisplatin—esophageal cancer	0.00596	0.00666	CcSEcCtD
Avanafil—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00586	0.00655	CcSEcCtD
Avanafil—PDE5A—Nitric oxide stimulates guanylate cyclase—NOS3—esophageal cancer	0.0058	0.0552	CbGpPWpGaD
Avanafil—Weight increased—Capecitabine—esophageal cancer	0.00574	0.00642	CcSEcCtD
Avanafil—Muscle spasms—Cisplatin—esophageal cancer	0.00573	0.00641	CcSEcCtD
Avanafil—Infestation NOS—Capecitabine—esophageal cancer	0.00563	0.00629	CcSEcCtD
Avanafil—Infestation—Capecitabine—esophageal cancer	0.00563	0.00629	CcSEcCtD
Avanafil—Vision blurred—Cisplatin—esophageal cancer	0.00562	0.00628	CcSEcCtD
Avanafil—Urinary tract infection—Capecitabine—esophageal cancer	0.00547	0.00611	CcSEcCtD
Avanafil—Haematuria—Capecitabine—esophageal cancer	0.00536	0.00599	CcSEcCtD
Avanafil—Epistaxis—Capecitabine—esophageal cancer	0.00531	0.00593	CcSEcCtD
Avanafil—Myalgia—Cisplatin—esophageal cancer	0.00508	0.00567	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00504	0.00563	CcSEcCtD
Avanafil—Urinary tract disorder—Capecitabine—esophageal cancer	0.00499	0.00557	CcSEcCtD
Avanafil—Oedema peripheral—Capecitabine—esophageal cancer	0.00498	0.00556	CcSEcCtD
Avanafil—Connective tissue disorder—Capecitabine—esophageal cancer	0.00496	0.00555	CcSEcCtD
Avanafil—Urethral disorder—Capecitabine—esophageal cancer	0.00495	0.00553	CcSEcCtD
Avanafil—Breast disorder—Methotrexate—esophageal cancer	0.00491	0.00549	CcSEcCtD
Avanafil—Infection—Cisplatin—esophageal cancer	0.00484	0.0054	CcSEcCtD
Avanafil—Nervous system disorder—Cisplatin—esophageal cancer	0.00477	0.00533	CcSEcCtD
Avanafil—Tachycardia—Cisplatin—esophageal cancer	0.00475	0.00531	CcSEcCtD
Avanafil—Skin disorder—Cisplatin—esophageal cancer	0.00473	0.00528	CcSEcCtD
Avanafil—Eye disorder—Capecitabine—esophageal cancer	0.00472	0.00527	CcSEcCtD
Avanafil—Flushing—Capecitabine—esophageal cancer	0.00469	0.00524	CcSEcCtD
Avanafil—Cardiac disorder—Capecitabine—esophageal cancer	0.00469	0.00524	CcSEcCtD
Avanafil—Angiopathy—Capecitabine—esophageal cancer	0.00458	0.00512	CcSEcCtD
Avanafil—Immune system disorder—Capecitabine—esophageal cancer	0.00456	0.0051	CcSEcCtD
Avanafil—Mediastinal disorder—Capecitabine—esophageal cancer	0.00455	0.00509	CcSEcCtD
Avanafil—Hypotension—Cisplatin—esophageal cancer	0.00455	0.00508	CcSEcCtD
Avanafil—Abdominal discomfort—Methotrexate—esophageal cancer	0.0045	0.00503	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00443	0.00496	CcSEcCtD
Avanafil—Mental disorder—Capecitabine—esophageal cancer	0.00442	0.00494	CcSEcCtD
Avanafil—Malnutrition—Capecitabine—esophageal cancer	0.0044	0.00491	CcSEcCtD
Avanafil—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00437	0.00488	CcSEcCtD
Avanafil—Back pain—Capecitabine—esophageal cancer	0.00425	0.00475	CcSEcCtD
Avanafil—Muscle spasms—Capecitabine—esophageal cancer	0.00423	0.00472	CcSEcCtD
Avanafil—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.0042	0.0047	CcSEcCtD
Avanafil—Infestation NOS—Methotrexate—esophageal cancer	0.00419	0.00468	CcSEcCtD
Avanafil—Infestation—Methotrexate—esophageal cancer	0.00419	0.00468	CcSEcCtD
Avanafil—Vision blurred—Capecitabine—esophageal cancer	0.00414	0.00463	CcSEcCtD
Avanafil—CYP3A4—Codeine and Morphine Metabolism—ABCC2—esophageal cancer	0.00413	0.0393	CbGpPWpGaD
Avanafil—Haematuria—Methotrexate—esophageal cancer	0.00399	0.00446	CcSEcCtD
Avanafil—Epistaxis—Methotrexate—esophageal cancer	0.00395	0.00441	CcSEcCtD
Avanafil—Vertigo—Capecitabine—esophageal cancer	0.00395	0.00441	CcSEcCtD
Avanafil—Palpitations—Capecitabine—esophageal cancer	0.00389	0.00434	CcSEcCtD
Avanafil—Body temperature increased—Cisplatin—esophageal cancer	0.00385	0.0043	CcSEcCtD
Avanafil—Cough—Capecitabine—esophageal cancer	0.00384	0.00429	CcSEcCtD
Avanafil—Hypertension—Capecitabine—esophageal cancer	0.0038	0.00424	CcSEcCtD
Avanafil—Arthralgia—Capecitabine—esophageal cancer	0.00374	0.00418	CcSEcCtD
Avanafil—Chest pain—Capecitabine—esophageal cancer	0.00374	0.00418	CcSEcCtD
Avanafil—Myalgia—Capecitabine—esophageal cancer	0.00374	0.00418	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00372	0.00415	CcSEcCtD
Avanafil—Urinary tract disorder—Methotrexate—esophageal cancer	0.00371	0.00415	CcSEcCtD
Avanafil—Urethral disorder—Methotrexate—esophageal cancer	0.00369	0.00412	CcSEcCtD
Avanafil—PDE5A—Hemostasis—CAPZA1—esophageal cancer	0.00366	0.0349	CbGpPWpGaD
Avanafil—Dry mouth—Capecitabine—esophageal cancer	0.00366	0.00409	CcSEcCtD
Avanafil—Infection—Capecitabine—esophageal cancer	0.00356	0.00398	CcSEcCtD
Avanafil—Nervous system disorder—Capecitabine—esophageal cancer	0.00352	0.00393	CcSEcCtD
Avanafil—Eye disorder—Methotrexate—esophageal cancer	0.00351	0.00393	CcSEcCtD
Avanafil—Tachycardia—Capecitabine—esophageal cancer	0.0035	0.00391	CcSEcCtD
Avanafil—Asthenia—Cisplatin—esophageal cancer	0.00349	0.0039	CcSEcCtD
Avanafil—Cardiac disorder—Methotrexate—esophageal cancer	0.00349	0.0039	CcSEcCtD
Avanafil—Skin disorder—Capecitabine—esophageal cancer	0.00349	0.00389	CcSEcCtD
Avanafil—Angiopathy—Methotrexate—esophageal cancer	0.00341	0.00381	CcSEcCtD
Avanafil—Immune system disorder—Methotrexate—esophageal cancer	0.0034	0.00379	CcSEcCtD
Avanafil—Mediastinal disorder—Methotrexate—esophageal cancer	0.00339	0.00379	CcSEcCtD
Avanafil—Hypotension—Capecitabine—esophageal cancer	0.00335	0.00375	CcSEcCtD
Avanafil—Diarrhoea—Cisplatin—esophageal cancer	0.00333	0.00372	CcSEcCtD
Avanafil—Mental disorder—Methotrexate—esophageal cancer	0.00329	0.00368	CcSEcCtD
Avanafil—Malnutrition—Methotrexate—esophageal cancer	0.00327	0.00366	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00327	0.00365	CcSEcCtD
Avanafil—CYP3A4—Fatty Acid Omega Oxidation—ADH7—esophageal cancer	0.00326	0.0311	CbGpPWpGaD
Avanafil—Insomnia—Capecitabine—esophageal cancer	0.00325	0.00363	CcSEcCtD
Avanafil—Back pain—Methotrexate—esophageal cancer	0.00317	0.00354	CcSEcCtD
Avanafil—Dyspepsia—Capecitabine—esophageal cancer	0.00316	0.00353	CcSEcCtD
Avanafil—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.0031	0.00346	CcSEcCtD
Avanafil—Vomiting—Cisplatin—esophageal cancer	0.00309	0.00346	CcSEcCtD
Avanafil—Fatigue—Capecitabine—esophageal cancer	0.00309	0.00346	CcSEcCtD
Avanafil—Vision blurred—Methotrexate—esophageal cancer	0.00308	0.00345	CcSEcCtD
Avanafil—Rash—Cisplatin—esophageal cancer	0.00307	0.00343	CcSEcCtD
Avanafil—Constipation—Capecitabine—esophageal cancer	0.00307	0.00343	CcSEcCtD
Avanafil—Dermatitis—Cisplatin—esophageal cancer	0.00307	0.00343	CcSEcCtD
Avanafil—Vertigo—Methotrexate—esophageal cancer	0.00294	0.00329	CcSEcCtD
Avanafil—Nausea—Cisplatin—esophageal cancer	0.00289	0.00323	CcSEcCtD
Avanafil—CYP3A4—Tryptophan metabolism—ALDH3A2—esophageal cancer	0.00287	0.0273	CbGpPWpGaD
Avanafil—CYP3A4—Fatty Acid Omega Oxidation—ADH1B—esophageal cancer	0.00286	0.0272	CbGpPWpGaD
Avanafil—Cough—Methotrexate—esophageal cancer	0.00286	0.00319	CcSEcCtD
Avanafil—Body temperature increased—Capecitabine—esophageal cancer	0.00284	0.00317	CcSEcCtD
Avanafil—PDE5A—Platelet homeostasis—NOS2—esophageal cancer	0.00281	0.0268	CbGpPWpGaD
Avanafil—Myalgia—Methotrexate—esophageal cancer	0.00279	0.00311	CcSEcCtD
Avanafil—Chest pain—Methotrexate—esophageal cancer	0.00279	0.00311	CcSEcCtD
Avanafil—Arthralgia—Methotrexate—esophageal cancer	0.00279	0.00311	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00277	0.00309	CcSEcCtD
Avanafil—Infection—Methotrexate—esophageal cancer	0.00265	0.00297	CcSEcCtD
Avanafil—CYP3A4—Irinotecan Pathway—ABCC2—esophageal cancer	0.00264	0.0251	CbGpPWpGaD
Avanafil—Nervous system disorder—Methotrexate—esophageal cancer	0.00262	0.00293	CcSEcCtD
Avanafil—Skin disorder—Methotrexate—esophageal cancer	0.00259	0.0029	CcSEcCtD
Avanafil—Asthenia—Capecitabine—esophageal cancer	0.00257	0.00288	CcSEcCtD
Avanafil—Pruritus—Capecitabine—esophageal cancer	0.00254	0.00284	CcSEcCtD
Avanafil—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.00253	0.0241	CbGpPWpGaD
Avanafil—Hypotension—Methotrexate—esophageal cancer	0.0025	0.00279	CcSEcCtD
Avanafil—Diarrhoea—Capecitabine—esophageal cancer	0.00246	0.00274	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00243	0.00272	CcSEcCtD
Avanafil—PDE5A—Hemostasis—ATP1B2—esophageal cancer	0.00243	0.0231	CbGpPWpGaD
Avanafil—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—esophageal cancer	0.00242	0.023	CbGpPWpGaD
Avanafil—Insomnia—Methotrexate—esophageal cancer	0.00242	0.0027	CcSEcCtD
Avanafil—Somnolence—Methotrexate—esophageal cancer	0.00237	0.00265	CcSEcCtD
Avanafil—Dizziness—Capecitabine—esophageal cancer	0.00237	0.00265	CcSEcCtD
Avanafil—Dyspepsia—Methotrexate—esophageal cancer	0.00235	0.00263	CcSEcCtD
Avanafil—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00231	0.00258	CcSEcCtD
Avanafil—Fatigue—Methotrexate—esophageal cancer	0.0023	0.00257	CcSEcCtD
Avanafil—Vomiting—Capecitabine—esophageal cancer	0.00228	0.00255	CcSEcCtD
Avanafil—Rash—Capecitabine—esophageal cancer	0.00226	0.00253	CcSEcCtD
Avanafil—Dermatitis—Capecitabine—esophageal cancer	0.00226	0.00253	CcSEcCtD
Avanafil—PDE5A—Platelet homeostasis—NOS3—esophageal cancer	0.00226	0.0215	CbGpPWpGaD
Avanafil—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC2—esophageal cancer	0.00226	0.0215	CbGpPWpGaD
Avanafil—Headache—Capecitabine—esophageal cancer	0.00225	0.00251	CcSEcCtD
Avanafil—PDE5A—Hemostasis—DOCK2—esophageal cancer	0.00219	0.0209	CbGpPWpGaD
Avanafil—CYP3A4—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.00219	0.0209	CbGpPWpGaD
Avanafil—Nausea—Capecitabine—esophageal cancer	0.00213	0.00238	CcSEcCtD
Avanafil—Body temperature increased—Methotrexate—esophageal cancer	0.00211	0.00236	CcSEcCtD
Avanafil—CYP3A4—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.00202	0.0192	CbGpPWpGaD
Avanafil—Asthenia—Methotrexate—esophageal cancer	0.00192	0.00214	CcSEcCtD
Avanafil—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.0019	0.018	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PFN1—esophageal cancer	0.00189	0.018	CbGpPWpGaD
Avanafil—Pruritus—Methotrexate—esophageal cancer	0.00189	0.00211	CcSEcCtD
Avanafil—Diarrhoea—Methotrexate—esophageal cancer	0.00183	0.00204	CcSEcCtD
Avanafil—Dizziness—Methotrexate—esophageal cancer	0.00177	0.00197	CcSEcCtD
Avanafil—Vomiting—Methotrexate—esophageal cancer	0.0017	0.0019	CcSEcCtD
Avanafil—Rash—Methotrexate—esophageal cancer	0.00168	0.00188	CcSEcCtD
Avanafil—Dermatitis—Methotrexate—esophageal cancer	0.00168	0.00188	CcSEcCtD
Avanafil—Headache—Methotrexate—esophageal cancer	0.00167	0.00187	CcSEcCtD
Avanafil—Nausea—Methotrexate—esophageal cancer	0.00159	0.00177	CcSEcCtD
Avanafil—CYP3A4—Xenobiotics—CYP2A6—esophageal cancer	0.00159	0.0151	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—CFL1—esophageal cancer	0.00153	0.0146	CbGpPWpGaD
Avanafil—CYP3A4—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00153	0.0145	CbGpPWpGaD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.00146	0.0139	CbGpPWpGaD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.00146	0.0139	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—GNG7—esophageal cancer	0.00145	0.0138	CbGpPWpGaD
Avanafil—CYP3A4—Estrogen metabolism—CYP1B1—esophageal cancer	0.00139	0.0132	CbGpPWpGaD
Avanafil—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.00136	0.013	CbGpPWpGaD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.0013	0.0123	CbGpPWpGaD
Avanafil—CYP3A4—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00123	0.0117	CbGpPWpGaD
Avanafil—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.0012	0.0114	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—HSPA5—esophageal cancer	0.00118	0.0112	CbGpPWpGaD
Avanafil—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.00109	0.0104	CbGpPWpGaD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.000924	0.0088	CbGpPWpGaD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.000919	0.00875	CbGpPWpGaD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.000912	0.00868	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—ABL1—esophageal cancer	0.000874	0.00832	CbGpPWpGaD
Avanafil—CYP3A4—Tryptophan metabolism—ALDH2—esophageal cancer	0.000866	0.00824	CbGpPWpGaD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000806	0.00767	CbGpPWpGaD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000749	0.00713	CbGpPWpGaD
Avanafil—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000723	0.00688	CbGpPWpGaD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000688	0.00655	CbGpPWpGaD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000658	0.00627	CbGpPWpGaD
Avanafil—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000656	0.00625	CbGpPWpGaD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.00065	0.00618	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—NOS2—esophageal cancer	0.00063	0.00599	CbGpPWpGaD
Avanafil—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000617	0.00587	CbGpPWpGaD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000568	0.0054	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—CREBBP—esophageal cancer	0.000566	0.00538	CbGpPWpGaD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000534	0.00508	CbGpPWpGaD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000531	0.00505	CbGpPWpGaD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000524	0.00499	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—NOS3—esophageal cancer	0.000506	0.00482	CbGpPWpGaD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000506	0.00482	CbGpPWpGaD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000499	0.00475	CbGpPWpGaD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000492	0.00469	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000488	0.00465	CbGpPWpGaD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.00043	0.0041	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000428	0.00407	CbGpPWpGaD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000405	0.00385	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000398	0.00379	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000392	0.00374	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—EP300—esophageal cancer	0.000385	0.00367	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.00037	0.00352	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000365	0.00347	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000302	0.00287	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000287	0.00273	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PIK3CA—esophageal cancer	0.000285	0.00271	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000284	0.0027	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—TP53—esophageal cancer	0.000276	0.00262	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000269	0.00256	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000229	0.00218	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000225	0.00215	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000215	0.00205	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000212	0.00202	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000115	0.0011	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000115	0.0011	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CA1—esophageal cancer	9.82e-05	0.000934	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SLC10A2—esophageal cancer	9.82e-05	0.000934	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CA2—esophageal cancer	8.98e-05	0.000855	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ADH7—esophageal cancer	8.35e-05	0.000795	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PLCE1—esophageal cancer	8.35e-05	0.000795	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ADH1B—esophageal cancer	7.32e-05	0.000697	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—TYMP—esophageal cancer	7e-05	0.000666	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP26A1—esophageal cancer	6.81e-05	0.000648	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ALOX15—esophageal cancer	6.63e-05	0.000631	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—TPI1—esophageal cancer	6.33e-05	0.000602	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTO1—esophageal cancer	6.33e-05	0.000602	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ALDOB—esophageal cancer	6.07e-05	0.000577	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GAPDH—esophageal cancer	5.84e-05	0.000556	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CRABP1—esophageal cancer	5.79e-05	0.000551	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GNG7—esophageal cancer	5.5e-05	0.000524	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ALDH2—esophageal cancer	5.16e-05	0.000491	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTT1—esophageal cancer	4.91e-05	0.000467	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP2A6—esophageal cancer	4.85e-05	0.000462	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ENO1—esophageal cancer	4.6e-05	0.000438	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PTGS1—esophageal cancer	4.6e-05	0.000438	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PSME1—esophageal cancer	4.53e-05	0.000431	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PSME2—esophageal cancer	4.53e-05	0.000431	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP1B1—esophageal cancer	3.91e-05	0.000372	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP19A1—esophageal cancer	3.67e-05	0.00035	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HMOX1—esophageal cancer	3.35e-05	0.000319	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ABCB1—esophageal cancer	3.22e-05	0.000306	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.15e-05	0.000205	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NOS3—esophageal cancer	1.93e-05	0.000183	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.76e-05	0.000168	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—EP300—esophageal cancer	1.47e-05	0.000139	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.08e-05	0.000103	CbGpPWpGaD
